Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study

Sci Rep. 2021 Aug 26;11(1):17211. doi: 10.1038/s41598-021-96744-3.

Abstract

The aim of this study was to investigate optimal loading doses prior to continuous infusion of meropenem in critically ill patients. A previously published and successfully evaluated pharmacokinetic model of critically ill patients was used for stochastic simulations of virtual patients. Maintenance doses administered as continuous infusion of 1.5-6 g/24 h with preceding loading doses (administered as 30 min infusion) of 0.15-2 g were investigated. In addition to the examination of the influence of individual covariates, a best-case and worst-case scenario were simulated. Dosing regimens were considered adequate if the 5th percentile of the concentration-time profile did not drop at any time below four times the S/I breakpoint (= 2 mg/L) of Pseudomonas aeruginosa according to the EUCAST definition. Low albumin concentrations, high body weight and high creatinine clearances increased the required loading dose. A maximum loading dose of 0.33 g resulted in sufficient plasma concentrations when only one covariate showed extreme values. If all three covariates showed extreme values (= worst-case scenario), a loading dose of 0.5 g was necessary. Higher loading doses did not lead to further improvements of target attainment. We recommend the administration of a loading dose of 0.5 g meropenem over 30 min immediately followed by continuous infusion.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use
  • Body Weight / physiology
  • Critical Illness / therapy*
  • Dose-Response Relationship, Drug
  • Humans
  • Infusions, Intravenous
  • Meropenem / administration & dosage
  • Meropenem / pharmacokinetics
  • Meropenem / therapeutic use*
  • Microbial Sensitivity Tests / methods
  • Patient Simulation
  • Prospective Studies
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / metabolism
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / physiology

Substances

  • Anti-Bacterial Agents
  • Meropenem